Topic: Pharmasset Inc.
(Reuters) - Gilead Sciences Inc struck a deal to buy biotechnology company Pharmasset Inc for about $11 billion in a huge and risky bet on the next generation of hepatitis C treatments.Gilead, the world's largest maker of HIV drugs, will pay $137 ...
(Reuters) - Gilead Sciences Inc struck a deal to buy biotechnology company Pharmasset Inc for about $11 billion in a huge bet on the next generation of hepatitis C treatments.Gilead, the world's largest maker of HIV drugs, will pay $137 per share ...
(Reuters) - Gilead Sciences Inc struck a deal to buy Pharmasset Inc for about $11 billion in a huge bet on hepatitis C treatments to diversify its portfolio.Gilead, the world's largest maker of HIV drugs, will pay $137 per share for each ...
(Reuters) - Pharmasset Inc said it started a late-stage trial of its experimental hepatitis C drug, sending the pharmaceutical company's shares up as much as 12 percent.The study will seek to ascertain whether the drug, PSI-7977, taken orally along with ribavirin -- ...
Pharmasset (VRUS) is a biotech company focused on the development of HCV therapeutics. The current standard of care for HCV is a combination of pegylated alpha interferon (IFN- ) and ribavirin taken for up to 48 weeks depending on patient response. PK), ...
Pharmasset says Roche will continue enrolling subjects in RG7128 trial after committee reviewPharmasset Inc. said Monday that it will continue enrolling patients in a clinical trial of RG7128, a drug that is designed to treat the liver disease hepatitis C.An independent committee ...
From Around the Web
Video Gallery
-
Citigroup Raised Its PT For Pharmasset ...
Citigroup raised its price target for Pharmasset Inc. (NASDAQ:VRUS ...2011-02-08 -
Pharmasset Finalizes 2-For-1 Stock Split
Hepatitis C drug developer Pharmasset Inc.(NASDAQ:VRUS) reported Tuesday ...2011-08-09 -
JAZZ, JVA, MXWL, PANL, STMP, VRUS ...
09/12/11 - The stock market had a very strong ...2011-09-13
